HIV-1 CH505 transmitted/founder gp120 vaccine with GLA-SE adjuvant

gp120-based HIV vaccine with GLA-SE adjuvant · HIV Vaccine Trials Network

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HIV-1 CH505 transmitted/founder gp120 vaccine with GLA-SE adjuvant, covering 2025-08-06 to 2025-08-06. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants [Phase 1]

See pricing